Modality
Fusion Protein
MOA
CAR-T CD19
Target
GIP-R
Pathway
Tau
SCDUCPTSD
Development Pipeline
Preclinical
~Jun 2010
→ ~Sep 2011
Phase 1
~Dec 2011
→ ~Mar 2013
Phase 2
~Jun 2013
→ ~Sep 2014
Phase 3
~Dec 2014
→ ~Mar 2016
NDA/BLA
~Jun 2016
→ ~Sep 2017
Approved
Dec 2017
→ Nov 2030
ApprovedCurrent
NCT08600580
379 pts·SCD
2017-12→2030-10·Completed
NCT05349157
756 pts·UC
2025-03→2030-11·Recruiting
NCT08903403
2,131 pts·UC
2021-06→2029-03·Not yet recruiting
+1 more trial
5,373 total pts2 indications
CompletedCurrentUpcoming
Catalysts (4)
2025-11-145mo agoPh3 Readout· UC
2029-03-173.0y awayPh3 Readout· UC
2030-10-174.5y awayPh3 Readout· SCD
2030-11-254.7y awayPh3 Readout· UC
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Complet…
Approved
Active
Approved
Not yet…
Approved
Recruit…
Catalysts
Ph3 Readout
2025-11-14 · 5mo ago
UC
Ph3 Readout
2029-03-17 · 3.0y away
UC
Ph3 Readout
2030-10-17 · 4.5y away
SCD
Ph3 Readout
2030-11-25 · 4.7y away
UC
RecruitingActiveCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08600580 | Approved | SCD | Completed | 379 | PANSS |
| NCT05349157 | Approved | UC | Recruiting | 756 | EASI-75 |
| NCT08903403 | Approved | UC | Not yet recr... | 2131 | HAM-D |
| NCT05358480 | Approved | UC | Active | 2107 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Datoglumide | AbbVie | Approved | CFTR | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |